Skip to main content
Ville N. Pimenoff on Muck Rack

Ville N. Pimenoff

Palo Alto
As seen in: Nature, Wiley Online Library, PLOS Medicine, MDPI, The World Bank Research Observer
Adj. Assoc. Professor @karolinskainst and @UniOulu, Visiting Scholar at @stanford.edu Virome, phages and Microbiome. Exposomics and Cancer.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ville N.

Contact Ville N., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Predicting optimal impact interventions in the post‐HPV vaccination world

|
By Matti Lehtinen, Marc Lipsitch, Ville N. Pimenoff, Karin B. Sundström
| Wiley Online Library Verified
CIS cervical carcinoma in situ DALY disability-adjusted-life-years EGW external genital warts IPD invasive pneumococcal disease LRCC lifetime risk of cervical cancer SCC squamous cervical cancer WHO World Health Organization 1 INTRODUCTION Prophylactic human papillomavirus (HPV) vaccination is a powerful tool that changes exposure to HPV infections and the risk of HPV-associated cancer morbidity. It also impacts the fundamental basis of how to perform optimal cervical screening.
Open in Who Shared Issue with article?

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study - npj Vaccines

|
By Penelope Gray, Filipe Colaço Mariz, Ville N. Pimenoff
| Nature Verified
Abstract Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings’ validity by comparing vaccine-induced antibody responses using two different immunoassays. 6558 16–17-year-old females participated in the FUTURE II (NCT00092534) and PATRICIA (NCT00122681) trials in 2002–2004. Both the quadrivalent and bivalent vaccine recipients (QVR and BVR) received three doses.
Open in Who Shared Issue with article?

Low methylation marker levels among human papillomavirus‐vaccinated women with cervical high‐grade squamous intraepithelial lesions

|
By Karolina Louvanto, Lisanne Verhoef, Ville N. Pimenoff, Pathology Amsterdam UMC
| Wiley Online Library Verified
1 INTRODUCTION Human papillomavirus (HPV) vaccinated birth cohorts of women are now reaching the age for cervical cancer screening programs.
Open in Who Shared Issue with article?
See all 8 articles